Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy
Nano Letters · 2025
DOI: 10.1021/acs.nanolett.5c03459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Qiliang Yin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Advanced Rare Earth Materials (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, P…. Hauptthemen laut MEDLINE: Glioma, Immunotherapy, Antigens, Neoplasm, Cancer Vaccines. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Jilin Province, China.
Abstract (Originalsprache)
Despite advances in immunotherapy, its efficacy against postoperative glioma recurrence remains limited. Here, we present a neoantigen-targeting peptide nanoshield that synergizes with glioma resection to eliminate residual tumor cells and prevent relapse. The nanoshield architecture is constructed using a multicationic protein (MCP) as the structural scaffold, which is assembled with the mutated isocitrate dehydrogenase 1 (muIDH1) neoantigen. The nanoshield vaccine enables lysosome-escaping muIDH1 delivery and inflammasome-mediated immune activation, generating polyfunctional CD8+ T cells. The results demonstrate superior and durable immunogenicity, with a 3-fold increase in CD8+ T cells and a 6-fold in vivo retention profile compared to free peptide controls, respectively. This leads to significant reduction in tumor size in prophylactic and therapeutic glioma models. Notably, it achieves over 40% improvement in terms of postoperative recurrence-free survival through combining the nanovaccine with antiprogrammed death-1 (aPD-1) therapy. Our immunotherapeutic strategy induces potent antitumor immunity, offering promising clinical potential for postoperative management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Advanced Rare Earth Materials (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China.
- Department of Cadre Ward, The First Hospital of Jilin University, Changchun 130021, China.
- State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China.
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China.
- Key Laboratory of Medical Molecular Virology of MOE/NHC/CAMS, School of Basic Medical Sciences, Fudan University, Shanghai 200032, P. R. China.
- Department of Chemistry, National University of Singapore, Singapore 117543, Singapore.
ORCID-Profile: Jingjing Li, Xihui Gao, Fan Wang, Qi Yue, Huaping Xu, Xiaogang Liu, Kai Liu
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Jilin Province, China
- Xiangfu Lab Research Project
- Project Agreement for Science & Technology Development, Jilin Province
- Animal Experiment Center of Jilin University
- Natural Science Foundation of Jilin Province
- National Key Research and Development Program of China
Zitieren
APA
Yin, Q., Li, J., Zhang, J., Leng, J., Zhang, K., Gao, X., Wang, F., Yue, Q., Ma, C., Xu, H., Liu, X., Zhang, H., & Liu, K. (2025). Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c03459
Vancouver
Yin Q, Li J, Zhang J, Leng J, Zhang K, Gao X, et al. Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c03459
BibTeX
@article{Yin2025,
author = {Yin, Qiliang and Li, Jingjing and Zhang, Jianhua and Leng, Jiyan and Zhang, Kexin and Gao, Xihui and Wang, Fan and Yue, Qi and Ma, Chao and Xu, Huaping and Liu, Xiaogang and Zhang, Hongjie and Liu, Kai},
title = {Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy},
journal = {Nano Letters},
year = {2025},
doi = {10.1021/acs.nanolett.5c03459}
}
EUVIMED